Chapman v. Labone

460 F. Supp. 2d 989, 2006 U.S. Dist. LEXIS 95053, 2006 WL 3196926
CourtDistrict Court, S.D. Iowa
DecidedSeptember 18, 2006
Docket4:01-cv-10565
StatusPublished
Cited by14 cases

This text of 460 F. Supp. 2d 989 (Chapman v. Labone) is published on Counsel Stack Legal Research, covering District Court, S.D. Iowa primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Chapman v. Labone, 460 F. Supp. 2d 989, 2006 U.S. Dist. LEXIS 95053, 2006 WL 3196926 (S.D. Iowa 2006).

Opinion

ORDER

LONGSTAFF, District Judge.

THE COURT HAS BEFORE IT defendants’ motion for summary judgment, filed *995 April 10, 2006. Plaintiffs responded May 26, 2006. Defendants submitted a reply June 8, 2006. On August 11, 2006, defendants submitted additional material in support of their motion.

Two other motions are also before the Court. On April 11, 2006, defendants filed a motion to strike plaintiffs’ expert witness. Plaintiffs responded to this motion on June 23, 2006. Defendants also filed a motion to strike plaintiffs’ summary judgment record and objections to unsubstantiated allegations on June 8, 2006. Plaintiffs resisted this motion on July 14, 2006. Defendants filed a reply July 20, 2006.

These matters are considered fully submitted.

I. BACKGROUND

This case evolves out of a random drug test conducted on a sample of plaintiff Michael Chapman’s urine. At the time, Chapman was employed by the Union Pacific Railroad Company (“Union Pacific”) as a trainman. As such, he was required by federal law to submit to periodic, random testing for controlled substances.

Defendants LabOne, Inc., a Missouri Corporation, and LabOne, Inc., a Delaware Corporation (collectively “LabOne") are private laboratories certified by the Department of Health and Human Services (“HHS”) to perform drug screens on certain transportation employees, including railroad employees. In August of 1999, Union Pacific was sending its samples to LabOne for testing.

On August 26, 1999, Chapman was selected for a random drug screen. LabOne returned a result of “substituted” “not consistent with normal human urine.” As a result of this finding, Union Pacific terminated Chapman.

II. MOTION TO STRIKE EXPERT WITNESS

Given the nature of the three pending motions, the Court must first address LabOne’s motion to strike Chapman’s expert witness, Dr. Vina Spiehler, Ph.D., DABFT (“Dr. Spiehler”). Chapman retained Dr. Spiehler to investigate La-bOne’s handing and testing of his urine sample. LabOne claims that Dr. Spiehler is unqualified to render an expert opinion in this case, and that her opinion is untrustworthy and unreliable. See Def. Br. in Supp. of Mot. to Strike Expert Witness at 5, 8.

Chapman has the burden of establishing the admissibility of Dr. Spiehler’s testimony. Lauzon v. Senco Products, Inc., 270 F.3d 681, 686 (8th Cir.2001). “In order to be admissible, expert testimony must be both relevant to a material issue and reliable.” Margolies v. McCleary, Inc., 447 F.3d 1115, 1120 (8th Cir.2006). That said, Rule 702 of the Federal Rules of Evidence, which governs the admissibility of expert testimony, is a rule of “admissibility rather than exclusion.” Lauzon, 270 F.3d at 686 (internal quotations omitted).

Under Rule 702, proposed expert testimony must meet the following three prerequisites: (1) “evidence based on scientific, technical, or other specialized knowledge must be useful to the finder of fact in deciding the ultimate issue of fact”; (2) the proposed expert witness must be “qualified to assist the finder of fact”; and (3) the proposed evidence “must be reliable or trustworthy in an evidentiary sense so that if the finder of fact accepts it as true it provides the assistance the finder of fact requires.” Lauzon, 270 F.3d at 686 (internal citations omitted).

A. Dr. Spiehler’s Knowledge and Experience

LabOne claims that Dr. Spiehler lacks the knowledge and experience to testify *996 regarding LabOne’s testing of Chapman’s urine sample. In particular, LabOne argues that Dr. Spiehler has no personal experience running or working in an HHS certified laboratory, and that she is not familiar with industry practice in August 1999.

Dr. Spiehler received her Ph.D. in Pharmacology and Toxicology from the University of California, Irvine School of Medicine in 1978. 1 In addition to her Ph.D., Dr. Spiehler holds a Master’s Degree in Analytical Chemistry and a Bachelor’s Degree in Chemistry. In 1984, she became a Diplómate of the American Board of Forensic Toxicology.

Since 1989, Dr. Spiehler has been a lab inspector for the Department of Health and Human Services’ National Laboratory Certification Program, the American Board of Forensic Toxicology’s (ABFT) Forensic Toxicology Laboratory Accreditation Program, and the College of American Pathologists’ Laboratory Certification Program. Dr. Spiehler also serves as a lecturer for California State University’s Extension Forensic Sciences Certificate Program and the California Criminalistics Institute. During her career, Dr. Spiehler has authored or co-authored more than 100 articles, many of which focus on laboratory drug testing. Since 1999, Dr. Spiehler has testified and/or been retained in more than 100 cases.

The Court finds that Dr. Spiehler possesses the education and training necessary to render an opinion regarding appropriate procedures for testing a urine sample. Dr. Spiehler is certified by HHS to inspect laboratories, such as LabOne, which perform federally-mandated occupational drug testing. It would be illogical to conclude, as LabOne argues, that Dr. Spiehler is qualified to inspect a laboratory to determine compliance with HHS regulations for the purpose of certification, but not for litigation.

B. Dr. Spiehler’s Opinion in this Case

The Court must also ensure that an expert opinion will be helpful to the jury in reaching its ultimate determination, and that the expert confines the scope of his or her opinions to areas of his or her expertise. See Wheeling, 254 F.3d at 715. Here, the parties do not dispute that an expert opinion is critical to the jury’s understanding of Chapman’s allegations. Furthermore, as discussed above, Dr. Spiehler is the type of expert who would ordinarily be qualified to render an opinion regarding the proper technique for employment related drug testing.

In her report, Dr. Spiehler opined that:

[Chapman’s specimen] was more likely than not dilute, that is, it had a creati-nine concentration that was below the range normal for urine from human males. The data supplied for [Chapman’s specimen] by LabOne do not support the report that the specimen was not human urine and this was not what was reported for the specimen. The data also do not support that the specimen was substituted to a degree of scientific certainty.

Def.App. in Supp. of Mot. to Strike Expert Witness at 3 (bold in original). In her deposition, Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Shaw v. Psychemedics Corporation
826 S.E.2d 281 (Supreme Court of South Carolina, 2019)
Wells v. Lamplight Farms, Inc.
303 F.R.D. 530 (N.D. Iowa, 2014)
Rodriguez v. Laboratory Corp. of America Holdings
13 F. Supp. 3d 121 (D.C. Circuit, 2014)
Landon v. Kroll Laboratory Specialists, Inc.
999 N.E.2d 1121 (New York Court of Appeals, 2013)
Landon v. Kroll Laboratory Specialists, Inc.
91 A.D.3d 79 (Appellate Division of the Supreme Court of New York, 2011)
Admiral Webster v. Psychemedics Corporation
Court of Appeals of Tennessee, 2011
Home Show Tours, Inc. v. Quad City Virtual, Inc.
827 F. Supp. 2d 924 (S.D. Iowa, 2011)
MECHDYNE CORP. v. Garwood
707 F. Supp. 2d 864 (S.D. Iowa, 2009)
Hall v. Central Intelligence Agency
538 F. Supp. 2d 64 (District of Columbia, 2008)
Quisenberry v. Compass Vision, Inc.
618 F. Supp. 2d 1223 (S.D. California, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
460 F. Supp. 2d 989, 2006 U.S. Dist. LEXIS 95053, 2006 WL 3196926, Counsel Stack Legal Research, https://law.counselstack.com/opinion/chapman-v-labone-iasd-2006.